Memantine
MEMANTINE, Memantine Hydrochloride
N-methyl-D-aspartate Receptor Antagonist
NADAC/unit
$0.0631
No Shortage
Tier 1: 170.5%
PA Req: 355.3%
24 Manufacturers
70 ANDAs
Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.
vs. brand MEMANTINE: Generic saves up to 99% per unit
Active Shortages
2025-04-28 Shortage reported, Upsher-Smith Laboratories, LLC
2025-04-28 Shortage reported, Upsher-Smith Laboratories, LLC
Generic Manufacturers
ABBVIE INCAJANTA PHARMA LTDALEMBIC PHARMACEUTICALS LTDAMNEAL PHARMACEUTICALS OF NEW YORK LLCAPOTEX INCAUROBINDO PHARMA LTDCHARTWELL MOLECULAR HOLDINGS LLCDR REDDYS LABORATORIES LTDHETERO LABS LTD UNIT VLUPIN LTDMACLEODS PHARMACEUTICALS LTDPURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALSPURACAP PHARMACEUTICAL LLCRENATA PLCRISING PHARMA HOLDING INCSETON PHARMACEUTICALS LLCSTRIDES PHARMA GLOBAL PTE LTDSUN PHARMACEUTICAL INDUSTRIES LTDUNICHEM LABORATORIES LTDUPSHER SMITH LABORATORIES LLCVITRUVIAS THERAPEUTICS INCYICHANG HUMANWELL PHARMACEUTICAL CO LTDYILING PHARMACEUTICAL LTDZYDUS LIFESCIENCES LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.